JP6047149B2 - 併用の医薬組成物およびその使用 - Google Patents

併用の医薬組成物およびその使用 Download PDF

Info

Publication number
JP6047149B2
JP6047149B2 JP2014509505A JP2014509505A JP6047149B2 JP 6047149 B2 JP6047149 B2 JP 6047149B2 JP 2014509505 A JP2014509505 A JP 2014509505A JP 2014509505 A JP2014509505 A JP 2014509505A JP 6047149 B2 JP6047149 B2 JP 6047149B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
alkenyl
alkynyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014509505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513138A (ja
JP2014513138A5 (enExample
Inventor
イー リュー，
イー リュー，
ピンダ レン，
ピンダ レン，
カタユーン ジェッセン，
カタユーン ジェッセン，
シン グオ，
シン グオ，
クリスチャン ロメル，
クリスチャン ロメル，
Original Assignee
インテリカイン， エルエルシー
インテリカイン， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテリカイン， エルエルシー, インテリカイン， エルエルシー filed Critical インテリカイン， エルエルシー
Publication of JP2014513138A publication Critical patent/JP2014513138A/ja
Publication of JP2014513138A5 publication Critical patent/JP2014513138A5/ja
Application granted granted Critical
Publication of JP6047149B2 publication Critical patent/JP6047149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014509505A 2011-05-04 2012-05-04 併用の医薬組成物およびその使用 Active JP6047149B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482568P 2011-05-04 2011-05-04
US61/482,568 2011-05-04
PCT/US2012/036688 WO2012151562A1 (en) 2011-05-04 2012-05-04 Combination pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2014513138A JP2014513138A (ja) 2014-05-29
JP2014513138A5 JP2014513138A5 (enExample) 2015-06-25
JP6047149B2 true JP6047149B2 (ja) 2016-12-21

Family

ID=47108075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014509505A Active JP6047149B2 (ja) 2011-05-04 2012-05-04 併用の医薬組成物およびその使用

Country Status (7)

Country Link
US (2) US20140357651A1 (enExample)
EP (1) EP2705181B1 (enExample)
JP (1) JP6047149B2 (enExample)
CN (1) CN103703174B (enExample)
CA (1) CA2836769C (enExample)
ES (1) ES2618489T3 (enExample)
WO (1) WO2012151562A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
EP2704723A4 (en) * 2011-05-06 2014-12-24 Univ California TREATMENT OF POLYCYSTIC DISEASES
WO2014153509A1 (en) * 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015002766A1 (en) * 2013-07-02 2015-01-08 Nikolai Khodarev Anti-tumor therapy
EP3164405A4 (en) * 2014-07-02 2018-05-23 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
MX2017001981A (es) 2014-09-11 2017-12-12 Univ California Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
WO2016064957A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
EP3236838B1 (en) * 2014-12-24 2022-09-07 The University of North Carolina at Chapel Hill Combined local delivery of therapeutic agents using interventional devices and radiation
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
SI3442535T1 (sl) * 2016-04-15 2023-01-31 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
LT3442980T (lt) 2016-04-15 2021-09-27 Cancer Research Technology Limited Heterocikliniai junginiai, kaip ret kinazės inhibitoriai
MX2019003694A (es) * 2016-10-07 2019-06-24 Abraxis Bioscience Llc Metodos para tratar cancer del tracto biliar.
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075795A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
SG11202010560QA (en) 2018-05-01 2020-11-27 Revolution Medicines Inc C26-linked rapamycin analogs as mtor inhibitors
CA3098692A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
WO2021157689A1 (ja) * 2020-02-07 2021-08-12 範行 東 細胞周期のｇ１期初期制御剤
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2010006086A2 (en) * 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
JP2014513138A (ja) 2014-05-29
US10172858B2 (en) 2019-01-08
HK1195793A1 (en) 2014-11-21
CA2836769C (en) 2018-11-13
US20140357651A1 (en) 2014-12-04
US20160287595A1 (en) 2016-10-06
EP2705181A1 (en) 2014-03-12
EP2705181B1 (en) 2016-12-21
CN103703174B (zh) 2017-05-10
CN103703174A (zh) 2014-04-02
EP2705181A4 (en) 2014-10-08
WO2012151562A1 (en) 2012-11-08
ES2618489T3 (es) 2017-06-21
CA2836769A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
JP6047149B2 (ja) 併用の医薬組成物およびその使用
JP6114296B2 (ja) 複数の医薬品を使用した治療レジメン
CN103491962B (zh) 激酶抑制剂的组合及其用途
JP6126615B2 (ja) キナーゼ阻害剤の組み合わせおよびそれらの使用
JP6130391B2 (ja) Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
JP2016512835A (ja) キナーゼ阻害剤の組み合わせ及びそれらの使用
US20160089371A1 (en) Combination of Kinase Inhibitors and Uses Thereof
WO2012154608A1 (en) Reactive mtor and pi3 kinase inhibitors and uses thereof
HK1195793B (en) Combination pharmaceutical compositions and uses thereof
HK1236441A1 (zh) 激酶抑制劑的組合及其用途
HK1236441A (en) Combination of kinase inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161118

R150 Certificate of patent or registration of utility model

Ref document number: 6047149

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250